As advised via Pharmac Tender announcement 31 May 2017, there is to be a change in the listing and future sole supply.

New listing HML from 1 November 2017 (due to supply issues listed one month earlier than tender announcement)

Cefuroxime Actavis Inj 750 mg 10 vial                         Pharmacode  2528894      Schedule price $9.85

Cefuroxime Actavis Inj 1.5 g 10 vial                  Pharmacode  2528908      Schedule price $14.36

Incumbent brand

Zinacef Inj 750 mg 5 vial                                      Pharmacode  276340         Schedule price $3.70

Zinacef Inj 1.5 g 1 vial                                           Pharmacode  276359         Schedule price $1.30

Delisting HML 1  February 2018. (All stocks are depleted)

Alternative product available

m-Cefuroxime Inj 750 mg 5 vial                        Pharmacode 2378140

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

Click here to read GSK notification.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author